Adage Capital Partners
TNGX icon

Adage Capital Partners’s Tango Therapeutics TNGX Stock Holding History

Adage Capital Partners’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$175M Sell
5,600,000
-7,209,485
-56% -$178M 0.25% 68
2026
Q1 		$268M Buy
12,809,485
+2,201,561
+21% +$30.6M 0.41% 45
2025
Q4 		$94M Buy
10,607,924
+8,096,924
+322% +$69.8M 0.14% 137
2025
Q3 		$21.1M Sell
2,511,000
-3,394,349
-57% -$23M 0.03% 453
2025
Q2 		$30.2M Buy
+5,905,349
New +$14.6M 0.05% 350
2024
Q4 		– Sell
-2,294,206
Closed -$17.7M – 958
2024
Q3 		$17.7M Hold
2,294,206
– – 0.03% 481
2024
Q2 		$19.7M Hold
2,294,206
– – 0.04% 439
2024
Q1 		$18.2M Sell
2,294,206
-1,105,794
-33% -$11.9M 0.03% 478
2023
Q4 		$33.7M Buy
3,400,000
+1,645,148
+94% +$14.3M 0.07% 290
2023
Q3 		$19.8M Buy
1,754,852
+564,971
+47% +$3.45M 0.04% 396
2023
Q2 		$3.95M Sell
1,189,881
-1,800
-0.2% -$6.47K 0.01% 694
2023
Q1 		$4.71M Sell
1,191,681
-8,319
-0.7% -$48.3K 0.01% 715
2022
Q4 		$8.7M Buy
1,200,000
+200,000
+20% +$1.41M 0.02% 667
2022
Q3 		$3.62M Hold
1,000,000
– – 0.01% 813
2022
Q2 		$4.53M Hold
1,000,000
– – 0.01% 809
2022
Q1 		$7.58M Buy
+1,000,000
New +$8.67M 0.01% 770
2021
Q3 		– Sell
-500,000
Closed -$5.69M – 1068
2021
Q2 		$5.69M Sell
500,000
-100,000
-17% -$1.12M 0.01% 810
2021
Q1 		$6.67M Hold
600,000
– – 0.01% 765
2020
Q4 		$6.86M Hold
600,000
– – 0.02% 653
2020
Q3 		$6.22M Buy
+600,000
New +$6.13M 0.02% 599

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Adage Capital Partners's TNGX Position: Q2 2026 in Review

Adage Capital Partners reduced its Tango Therapeutics (TNGX) stake by 56% in Q2 2026, selling an estimated $178M and leaving 5,600,000 shares worth $175M. The position accounts for 0.25% of the portfolio, ranked #68.

Adage Capital Partners first reported a position in TNGX in Q3 2020 and has held it in 20 quarters since. The position peaked at $268M in Q1 2026. 247 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Adage Capital Partners held 5,600,000 shares of Tango Therapeutics worth $175M as of Q2 2026.
  • Adage Capital Partners sold 7,209,485 Tango Therapeutics shares in Q2 2026, an estimated $178M.
  • Tango Therapeutics made up 0.25% of Adage Capital Partners's portfolio in Q2 2026, its #68 holding.
  • Adage Capital Partners first reported a position in Tango Therapeutics in Q3 2020 and has held it in 20 quarters since.
  • Adage Capital Partners's Tango Therapeutics position peaked at $268M in Q1 2026.
  • 247 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.